Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

BCLC Staging System (2022 Update)

The BCLC system (2022 update) is the standard staging classification for Hepatocellular Carcinoma (HCC).

Evidence-based context for fast calculator use

Purpose:
BCLC 2022 staging classifies hepatocellular carcinoma by tumor burden, liver function, and performance status to guide HCC treatment strategy.
Population:
patients undergoing liver-function, hepatocellular carcinoma staging, imaging, or transplant assessment
Factors:
Performance Status, Child-Pugh Class, Tumor Burden
Reference:
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-693.
HomeBCLC Staging System (2022 Update)
Pin your most used calculators here by clicking the star in the dropdown.

BCLC Staging System (2022 Update)

Clinical Context & Background

The BCLC system (2022 update) is the standard staging classification for Hepatocellular Carcinoma (HCC). It links staging with treatment indications and prognosis. Updates in 2022 acknowledge the role of systemic therapy for select intermediate-stage (B) patients and establish immunotherapy (Atezolizumab + Bevacizumab) as the standard for advanced stages.
Primary Source EvidenceReig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-693.
Formula Logic
Classification based on Tumor Burden, Liver Function (Child-Pugh), and Performance Status (ECOG).

Reference Data

BCLC StageClassificationTreatment Strategy (2022)
Stage 0Very EarlyAblation (Resection in select cases)
Stage AEarlyResection / Transplant / Ablation
Stage BIntermediateTACE (or Systemic if diffuse/high burden)
Stage CAdvancedSystemic Therapy (Atezo/Bev)
Stage DTerminalBest Supportive Care

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use BCLC Staging System (2022 Update) when bCLC 2022 staging classifies hepatocellular carcinoma by tumor burden, liver function, and performance status to guide HCC treatment strategy.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Stage 0 through Stage D.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate liver reserve, portal hypertension, tumor burden, vascular invasion, extrahepatic disease, performance status, and transplant policy.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Liver function, HCC stage, imaging category, and transplant criteria are complementary but not interchangeable.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing liver-function, hepatocellular carcinoma staging, imaging, or transplant assessment

How to apply this result

For a representative case, verify Performance Status, Child-Pugh Class, Tumor Burden, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Liver / HCC hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

ALBI ScoreALBI-T ScoreHKLC Staging System

Frequently Asked Questions

When should BCLC Staging System (2022 Update) be used?

Use it for patients undergoing liver-function, hepatocellular carcinoma staging, imaging, or transplant assessment when all required inputs and the intended clinical setting are confirmed.

Can BCLC Staging System (2022 Update) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.